Literature DB >> 12577054

Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice.

Salah-Eddine Lamhamedi-Cherradi1, Shi-Jun Zheng, Kimberly A Maguschak, Jacques Peschon, Youhai H Chen.   

Abstract

TRAIL, the tumor necrosis factor-related apoptosis-inducing ligand, selectively induces apoptosis of tumor cells, but not most normal cells. Its role in normal, nontransformed tissues is not clear. We report here that mice deficient in TRAIL have a severe defect in thymocyte apoptosis-thus, thymic deletion induced by T cell receptor ligation is severely impaired. TRAIL-deficient mice are also hypersensitive to collagen-induced arthritis and streptozotocin-induced diabetes and develop heightened autoimmune responses. Thus, TRAIL mediates thymocyte apoptosis and is important in the induction of autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12577054     DOI: 10.1038/ni894

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  104 in total

1.  B lymphocytes are resistant to death receptor 5-induced apoptosis.

Authors:  Roslyn N Crowder; Hong Zhao; W Winn Chatham; Tong Zhou; Robert H Carter
Journal:  Clin Immunol       Date:  2011-01-28       Impact factor: 3.969

Review 2.  Resistance to TRAIL and how to surmount it.

Authors:  Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

Review 3.  TRAIL, Bim, and thymic-negative selection.

Authors:  Shi-Jun Zheng; Youhai H Chen
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

4.  Fas apoptosis inhibitory molecule regulates T cell receptor-mediated apoptosis of thymocytes by modulating Akt activation and Nur77 expression.

Authors:  Jianxin Huo; Shengli Xu; Kong-Peng Lam
Journal:  J Biol Chem       Date:  2010-02-23       Impact factor: 5.157

Review 5.  Are we really on the right TRAIL?

Authors:  Erika Cretney; Adam P Uldrich; Stuart P Berzins; Andreas Strasser; Dale I Godfrey; Mark J Smyth
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

6.  Serum-soluble TRAIL: a potential biomarker for disease activity in myositis patients.

Authors:  Hang Zhou; Yunchao Wang; Kuo Bi; Haiyu Qi; Shuju Song; Mingzhu Zhou; Letian Chen; Guochun Wang; Ting Duan
Journal:  Clin Rheumatol       Date:  2019-01-15       Impact factor: 2.980

7.  TRAIL limits excessive host immune responses in bacterial meningitis.

Authors:  Olaf Hoffmann; Josef Priller; Timour Prozorovski; Ulf Schulze-Topphoff; Nevena Baeva; Jan D Lunemann; Orhan Aktas; Cordula Mahrhofer; Sarah Stricker; Frauke Zipp; Joerg R Weber
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

8.  The TRAIL to arthritis.

Authors:  George C Tsokos; Maria Tsokos
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

9.  CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis.

Authors:  Zhongyu Liu; Xin Xu; Hui-Chen Hsu; Albert Tousson; Ping-Ar Yang; Qi Wu; Cunren Liu; Shaohua Yu; Huang-Ge Zhang; John D Mountz
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

10.  Alveolar epithelial cells in idiopathic pulmonary fibrosis display upregulation of TRAIL, DR4 and DR5 expression with simultaneous preferential over-expression of pro-apoptotic marker p53.

Authors:  Khondoker M Akram; Nicola J Lomas; Nicholas R Forsyth; Monica A Spiteri
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.